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Abstract: Scaffolds are thought to be a key element needed for successful cartilage repair treatments,
and this prospective extension study aimed to evaluate long-term structural and clinical outcomes
following osteochondral defect treatment with a cell-free biphasic scaffold. Structural outcomes were
assessed using quantitative 3-D magnetic resonance imaging (MRI) and morphological segmentation
to determine the percentage of defect filling and repair cartilage T2 relaxation times, and clinical
outcomes were determined with the modified Cincinnati Rating System, and the Knee Injury and
Osteoarthritis Outcome Score (KOOS). Seventeen subjects with osteochondral defects in the knee
were treated with ChondroMimetic scaffolds, from which 15 returned for long-term evaluation at a
mean follow-up of 7.9 ± 0.3 years. The defects treated were trochlear donor sites for mosaicplasty in
13 subjects, and medial femoral condyle defects in 2 subjects. MRI analysis of scaffold-treated defects
found a mean total defect filling of 95.2 ± 3.6%, and a tissue mean T2 relaxation time of 52.5 ± 4.8 ms,
which was identical to the T2 of ipsilateral control cartilage (52.3 ± 9.2 ms). The overall modified
Cincinnati Rating System score was statistically significant from baseline (p = 0.0065), and KOOS
subscales were equivalent to other cartilage repair techniques. ChondroMimetic treatment resulted
in a consistently high degree of osteochondral defect filling with durable, cartilage-like repair tissue
at 7.9 years, potentially associated with clinical improvement.
Keywords: biphasic scaffold; osteochondral defect; cartilage repair; quantitative MRI; calcium
phosphate
1. Introduction
Articular cartilage damage continues to present a therapeutic challenge, and despite multiple and
differing approaches ranging from bone marrow stimulation [1], autologous chondrocyte implantation
(ACI) [2], and various grafting procedures incorporating allografts and autografts [3,4], none are
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recognized as sufficient. Recent reviews demonstrate that clinical research has failed to substantiate the
superiority of one technique or product, in large part because of heterogeneous patient demographics,
the differing etiologies of defects, and the varying study designs and outcome measures [5–7]. The lack
of longer term (5–10 years) clinical evidence in cartilage repair further limits evidence-based treatment
algorithms. Nonetheless, the fundamental goal of any cartilage repair treatment should be to avoid
the progression to secondary osteoarthritis [8,9], by achieving structural repair that is comparable to
native hyaline cartilage, and thereby assuring long-term durability, joint function, and pain relief.
ChondroMimetic (Collagen Solutions, Plc) was developed to be a cell-free, osteochondral scaffold
for use in cartilage repair. The biphasic implant comprises a 2 mm, unmineralized, type I bovine
collagen and chondroitin-6-sulphate glycosaminoglycan (collagen/GAG) chondral layer, coupled
to a 6mm, mineralized, subchondral bone layer, containing collagen/GAG and calcium phosphate
brushite. These two distinct layers are separated by a continuous or ‘soft’ interface that closely
mimics the compositional transition between mineralized bone and unmineralized cartilage at the
tide mark [10]. As an open-cell foam, the ChondroMimetic scaffold which allows compression during
surgical handling for press-fit implantation, followed by auto-expansion to fit the defect shape, bridging
any gaps or irregularities [11]. In a defect with stable margins, ChondroMimetic offers structural
and mechanical protection for the marrow-derived blood clot, similarly to mechanisms claimed for
other techniques (e.g., autologous matrix-induced chondrogenesis (AMIC) [12], BST-CarGel [13]).
Large animal preclinical studies with ChondroMimetic demonstrated a consistency in osteochondral
repair characterized by a high degree of cartilage defect filling with a hyaline-like repair tissue in both
medial femoral condyle and trochlear defect sites [14–16].
Since long term data (>5 years post treatment) is fast becoming a required component for clinical
decision-making in cartilage repair, the aim of this prospective extension study was to determine the
long-term effectiveness of ChondroMimetic treatment of osteochondral defects in subjects enrolled in
a previous short-term study. Using 3D quantitative magnetic resonance imaging (MRI) techniques,
a consistently high degree of osteochondral defect filling with durable, cartilage-like repair tissue was
found at 7.9 years and potential clinical benefit.
2. Methods
2.1. Study Design and Participants
This study was an extension of a prospective, interventional study which enrolled 17 subjects
between February 2009 and March 2010 at a single clinical site (formerly unpublished). The 17 eligible
subjects (8 males, 9 females) were between 18 and 50 years of age with at least one osteochondral
defect measuring <12 mm in the knee. Subjects with a body mass index >40 kg/m2 or a previous
cartilage repair treatment in the index knee were excluded. All subjects who participated in the
original interventional study were eligible to be enrolled in the extension study, which was designed
to provide long-term follow up at a single time point which included a clinic visit and a single MRI
scan. All subjects were asked to provide written informed consent prior to extension study activities,
which were approved by national and local ethics review boards. Both studies were performed in
accordance with guidelines for Good Clinical Practice. This extension study was registered with
ClinicalTrials.gov (NCT03385642).
2.2. Interventional Details
During the original interventional study, following osteochondral defect preparation, the pre-
loaded implant was hydrated with saline through the hydration portal in the delivery device,
which was then positioned perpendicular to the defect with the tip inserted to the to the full defect
depth. Simultaneous advancement of the implant and withdrawal of the device tip left the implant to
expand into the defect volume. ChondroMimetic scaffolds were used to treat mosaicplasty donor sites
in the trochlea in 15/17 subjects concurrent with mosaicplasty treatment of 12 femoral condyle defects
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and 3 ankle defects. ChondroMimetic scaffolds were also used to treat primary femoral condyle defects
in 2/17 subjects. Ultimately, scaffolds chosen for use ranged from 6.5–8.5 mm in diameter. None of the
subjects included in the study had tibial articular defects.
2.3. Outcome Measures
Neither the subjects nor the investigator were blinded to treatment in this study, but the
administration of identical validated questionnaires, standardized acquisition of MRI scans,
and subsequent semi-automated, quantitative MRI analysis of repair tissue structure by an independent
3rd party minimized method and analysis bias.
2.3.1. Structural Repair
Repair tissue structure, defined as the quantity (i.e., degree of defect filling (%)) and quality
(T2 relaxation time) of new cartilage tissue, was assessed by three-dimensional (3D) quantitative
MRI conducted at an imaging core lab (Qmetrics Technologies, Rochester, NY, USA) using, validated
segmentation and 3D reconstruction techniques [17,18] which have been applied in Phase 3 clinical
trials of cartilage repair and multiple osteoarthritis studies [19–21]. Standardized MRI scans were
acquired for each subject upon enrolment into the extension study with a Siemens 3T MAGNETOM®
Verio, A Tim+Dot System and dedicated Tx-Rx CP extremity coil at a single, prequalified and trained
MRI clinic. Technician training and scanner magnet qualification were conducted prior to trial activities.
A uniformity and linearity phantom scan was performed for quality control. Imaging phantoms within
the field of view served as internal controls.
The imaging protocol was designed to provide very high spatial resolution with high in-plane
resolution and thin slices for all sequences. The study images were acquired using a fat-suppressed 3D
spoiled gradient-echo (FS SPGR) sequence in sagittal and axial planes (slice thickness: 2 mm), and a 2D
dual-echo fat-suppressed fast spin-echo (FS dual echo) sequence in the sagittal plane (slice thickness
1.2 mm). For morphological analyses of cartilage, cartilage defects, bone and bone defects, sagittal
and axial FS SPGR series were used. Sagittal FS dual-echo series were used for T2 analyses. All scans
were sent to an imaging core lab for centralized scan quality review, storage, and quantitative analysis.
The sagittal 3D FS SPGR series and the sagittal FS dual echo series were segmented for bone and
cartilage using a semi-automated atlas-based segmentation method [17]. The segmentations were
reviewed and edited, if needed, by a musculoskeletal radiologist with expertise in cartilage repair.
Original cartilage and bone defect boundaries for each subject were manually established on FS SPGR
and FS dual echo segmentations using edited segmentation of MRI scans (sagittal dual echo) obtained
10 days post-operatively in the original interventional ChondroMimetic study.
The segmented 3D volume of new repair tissue at follow-up was then used to quantitatively
determine the degree of defect filling (%) and the mean T2 relaxation time of cartilage repair tissue.
Filling was calculated as a ratio of new repair tissue (bone and cartilage) to the original osteochondral
defect volume. In cases where multiple donor sites in the same knee were treated, confluence of
defects was observed in the trabecular bone resulting in a single defect volume and a single fill ratio.
A radiologist-selected region of interest (ROI) of cartilage on an untouched area of the trochlea in the
same knee was segmented and analyzed for each subject as a native T2 control.
2.3.2. Clinical Benefit
Clinical outcomes at the extension study timepoint were evaluated using two subject self-reported
questionnaires. The modified Cincinnati Rating System has 8 components in the score, assessing pain,
swelling, giving way, overall activity levels and walking, stairs, running activity, and jumping/twisting.
With this instrument, a higher score is a better result and a lower score implies greater disability.
Grading of the scores followed that proposed by Bentley et al. [22], where a score of <30 as “poor”,
30–54 as “fair”, 55–79 as “good” and >80 as “excellent”.
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The Knee injury and Osteoarthritis Outcome Score (KOOS) [23] in the Likert format has 5 subscales:
Pain, other Symptoms, Function in daily living, Function in Sport and Recreation and knee-related
Quality of Life. Scores are attributed by dimension, ranging from 0 to 100 (high score better outcome).
The KOOS score was not administered in the original interventional study, and therefore baseline
scores were not available.
2.4. Statistical Considerations
All statistical analyses were conducted using SAS 9.4 or above (SAS Institute Inc., Cary, NC, USA).
All graphs were produced in Microsoft Excel 2016 (Microsoft Inc., Redmond, WA, USA). For statistical
analysis purposes, baseline was defined for clinical outcome data as data collected pre-operatively,
and for MRI analyses, 10 day post-operatively. Quantitative structural repair outcomes underwent
univariate and descriptive analyses, investigating the scores at the single study time point for the degree
of defect filling (total volume), and for repair tissue quality (T2). Clinical outcome data underwent
univariate and descriptive analyses, for both modified Cincinnati Rating System and KOOS subscales.
Statistical comparisons used Student’s t-tests.
3. Results
3.1. Enrolment and Subject Characteristics
Enrolment into the extension study targeted 8-year follow-up for the 17 subjects in the original
clinical study. Ultimately, 15 of the original 17 subjects completed the single extension study visit,
and their demographic characteristics are shown in Table 1. The study population was balanced
by gender, and subjects received from 1 to 5 ChondroMimetic scaffolds, per knee, to treat trochlear
donor sites for mosaicplasty in 13 subjects, and medial femoral condyle defects in 2 subjects. A total
of 14 additional procedures since enrolment into the original interventional study were recorded by
12 individual subjects. The majority of these interventions involved either arthroscopy of knees or
ankles or intra-articular injections. No interventions were specifically attributed to the ChondroMimetic
treatment by the Investigator.
Table 1. Follow-up Characteristics of Trial Subjects ‡.
Characteristic Chondromimetic (n = 15)
Consented subjects from original study, n (%) 15 (88)
Follow-up, years 7.9 ± 0.3




Body Mass Index, kg/m2 25.3 ± 4.2
Smokers, n (%) 2 (13.3)
Index defects and implants
Mosaicplasty donor site(s), n (%) 13 (86.7)
Medial femoral condyle defect, n (%) 2 (13.3)
Defect volume including missing bone, mm3 ¶ 1573 ± 1233
ChondroMimetic Implants/knee, median (range) 2 (1–5)
Follow-up Pain, n (%) *
No knee pain 11 (73.3)
Mild knee pain 2 (13.3)
Moderate knee pain 2 (13.3)
Follow-up Activity Level, n (%) *
Unlimited 8 (53)
Slightly limited 4 (27)
Moderately limited 3 (20)
Additional interventions since treatment
Index knee related procedures ˆ 12
Non-knee related procedures 2
‡ Plus-minus values are means ± standard deviation unless otherwise indicated. ¶ Determined using quantitative
3D magnetic resonance imaging (MRI) of 10 days postoperative scans. ˆ Hyaluronic acid injection (4); microfracture
of new primary lesion (3); second-look arthroscopy (5). * From physical examination and standardized interview
during the 8-year study visit.
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There were no withdrawals from the extension study. The only missing data in the study was
MRI analysis from 1 subject who did not yield usable scans due to movement.
3.2. Repair Outcomes
3.2.1. Structural Repair
The quantity and quality of ChondroMimetic repair tissues was determined for 14 subjects (the MRI
from the fifteenth subject was unusable due to movement; see Table 2). ChondroMimetic-treated
osteochondral defects at 7.9 years post-treatment demonstrated a substantial degree of defect filling
of 95.2 ± 3.6%. Figure 1 shows the Total Defect Fill (%) of individual subjects and illustrates a
low variability and consistently high degree of defect filling following ChondroMimetic treatment.
In addition, subjects treated with ChondroMimetic had a mean T2 relaxation time of 52.5 ± 4.8 ms for
the cartilage repair tissue ROI, which was nearly equal to the T2 relaxation time of the ipsilateral native
control cartilage regions (52.3 ± 9.2 ms (p = 0.94)), and suggestive of a very similar tissue biochemical
make-up and structure. The T2 standard deviations calculated for each repair tissue volume were
comparable to native cartilage (17.3 ± 3.3 vs. 13.1 ± 5.3 ms), with a variance that was statistically equal
to that of native cartilage (p = 0.11 by F-test).
Table 2. Structural repair outcomes by 3 dimensional MRI at 7.9 years follow-up (n = 14).
Variable Outcome
Total defect fill (%) 95.2 ± 3.6 (89.8, 99.9)
T2 relaxation time (ms)
Cartilage repair tissue 52.5 ± 4.8 (44.4, 58.5) +
Ipsilateral native cartilage 52.3 ± 9.2 (39.9, 78.5)
Values are presented as means ± standard deviation (min, max). T2 = transverse relaxation time; MRI = magnetic
resonance imaging. + p = 0.94 by Student’s t-test compared to native cartilage.
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Figure 1. Total Defect Fill (%) by quantitative MRI for individual subjects at a mean followup of 7.9 
years after ChondroMimetic treatment. Total Defect Fill (%) was determined using 3D quantitative 
Figure 1. Total Defect Fill (%) by quantitative MRI for individual subjects at a mean followup of 7.9 years
after ChondroMimetic treatment. Total Defect Fill (%) was determined using 3D quantitative magnetic
resonance imaging by calculating the ratio of the new repair tissue (bone and cartilage) volume at
followup, to original defect (bone and cartilage) volume acquired from 10 days post-operative scans
(baseline). (n = 14).
Using each scan series, full 3D reconstructions were generated of treated knees at the 10-day
post-operative baseline, and at follow-up, to assist in visualizing the morphological impact of
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ChondroMimetic repair. Figure 2 illustrates a representative reconstruction conducted for a 29-year-old
female subject who received 5 ChondroMimetic scaffolds in the trochlea, which are clearly visible
filling the newly treated osteochondral defects in Figure 2A by 2D MRI, and are similarly visible in the
3D rendering (Figure 2B). At the follow-up after 8 years and 3 months, both the subchondral bone and
cartilage aspects of the original defects appear as near-normal in both Figure 2C,D, compared with
ipsilateral control regions in Figure 2E.
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Figure 2. Longitudinal MRI reconstruction of a ChondroMimetic-treated subject knee at 10 days
(A,B) and 8 years, 3 months (C,D). (A) By 2D MRI, 5 ChondroMimetic implants ca be observed with
hyper-intense peri-implant boundaries, and lack of cartilage-like signal (white arr w). (B) 3D rendering
of k e yields ChondroMimetic implants (green) surrounded by cartil ge (brown) by automated
softwar based on MRI signal. (C) At the follow-up after 8 years and 3 months, treated bone defects
are filled with bony repair tissue and the treated cartilage defect is filled with cartilaginous r pair
tissue. (D) Automated rendering demonstrates cartilaginous tissue in repaired defects congruous with
surrounding cartilage. (E) The trochlear control region of interest (filled red circle) of native cartilage
used for T2 relaxation time comparison. The open purple circle shows an unused, alternate control
region of interest.
3.2.2. Clinical Benefit
The modified Cincinnati Rating System overall score at the study timepoint was 80.9 ± 15.5,
which was statistically significant from baseline (p = 0.0065) and represents a grading of ‘excellent’.
The KOOS subscale data are presented in Figure 3. The mean pain score was 90.0 ± 11.4. The mean
symptom score was 80.0 ± 15.8. The mean function in daily living (ADL) score was 93.4 ± 9.1. The mean
function in sports and recreational activities (Sports/Rec) score was 68.7 ± 24.7. The knee related quality
of life (QOL) mean score was 66.7 ± 22.2.
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4. Discussion
The mai finding of the current study is that voluminous, high quality repair cartilage results
from ChondroMimetic treatment of osteochondral defects after 7.9 years, supporting the hypothesis
that ChondroMimetic brings consistent and durable long-term structural repair with an appropriate
safety profile. Improvements in clinical outcomes were highly significant over the baseline (p < 0.0065)
for the 7.9-year follow-up, which suggests a benefit of ChondroMimetic treatment when used as
backfill for mosaicplasty donor sites. The use of validated, three-dimensional quantitative MRI [17,18],
which assessed the repair tissue quantity and quality, is a particularly valuable aspect of this study, with a
high level of standardization and precision and conducted under Good Clinical Practice guidelines.
The high degree of defect filling by new bone and repair cartilage seen in ChondroMimetic defects
at 7.9 years (95.2%) is a critical outcome, as any joint resurfacing should aim to reestablish mechanical
homeostasis and anatomical shape with an integrated surface, particularly since chondrocyte-mediated
biosynthesis, remodeling, and either tissue repair or degradation over time is dependent on the
mechanical loading conditions of cartilage [24]. Normal surface morphology and joint articulation
would be expected to improve biomechanical conditions and inhibit the degeneration of defect
and peri-defect tissues and slow the progression of secondary osteoarthritis [8,9]. This particular
outcome was not fully unexpected, since critical size osteochondral defects in goat knees treated
with ChondroMimetic scaffolds yielded similarly striking filling [14]. Furthermore, this level of
defect filling is greater than that resulting from another off-the-shelf biological scaffold, BST-CarGel,
at 5 year spost-treatment, which produced %Fill of 93.79%, as determined by very similar quantitative
MRI methods [13].
Quantitative MRI also identified durable, high quality cartilage repair tissue by T2 relaxation
time for ChondroMimetic-treated defects. T2 relaxation time is well known to be sensitive to,
and highly dependent on, the extracellular cartilage matrix and particularly the collagen network
structure, orientation, as well as macromolecular concentration, and tissue hydration [25–29].
When acquired under standardized conditions coupled with three-dimensional segmentation of
regions of interest, T2 relaxation time has been an effective, quantitative method for comparing repair
tissue to native articular cartilage, and/or to repair tissue resulting from another treatment [13,30,31].
Here, the determination of the quality of repair is evidenced by the closeness of measured T2 values
to that found from the ipsilateral normal articular cartilage (52.3 vs. 52.5 ms, p = 0.94), indicating a
near-normal level of tissue quality after 7.9 years. The overall level of repair tissue organization achieved
is further evidenced by the T2 standard deviations calculated for each repair tissue volume, which were
comparable to native cartilage with a variance that was statistically equal to that of native cartilage.
In contrast, a tissue with regions of differing organization, or of mixed hyaline-fibrocartilage tissue,
would be expected to have a more widespread variance than normal cartilage. When comparing to T2
outcomes resulting from MRI studies with other scaffolds, ChondroMimetic repair tissue demonstrated
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a similar closeness to native control cartilage as a study with Hyalograft C [32] in the knee, but was
improved compared to the MaioRegen scaffold in the ankle [30], and BST-CarGel in the knee [13],
neither of which resulted in T2 relaxation times similarly close to control cartilage. This finding
also confirms consistency of repair in improved collagen-based organization and content, which are
necessary components for long-term durability of cartilage since collagen breakdown is considered to
be a critical step in the progression of osteoarthritis [33,34].
It may be considered a limitation of the study that ChondroMimetic was used as back-fill treatment
for the majority of osteochondral defects (13/15) in the study, particularly since it is generally believed
that mosaicplasty donor sites are: (1) not exposed to weight bearing forces; and (2) ultimately filled with
a fibrocartilage through self-repair processes and are asymptomatic [35]. To the contrary, donor sites
experience high loads with daily activities, depending on their size and location, from 1.3 times up to
7.8 times body weight [36]. Furthermore, Andrade et al. [37] reviewed 21 original mosaicplasty studies
comprising 1726 patients and found that donor site morbidity reportedly occurs in 5.9–16.9% of cases
and manifests through crepitation and knee stiffness, instability during activities of daily living, and
persistent pain. The fact that in this study no adverse events or symptoms were reported to be related
to donor sites or ChondroMimetic implants over the 7.9 year follow-up, and modified Cincinnati and
KOOS scores demonstrated a high level of satisfaction, demonstrates that ChondroMimetic treatment
was safe and may suggest some clinical benefit, further supported by the MRI-assessed high quality
cartilage repair. Furthermore, the regeneration of bone and cartilage to near-native levels of fill
and biochemical structure suggest that Chondromimetic may fit into an algorithm for treatment of
full-thickness, primary cartilage lesions. Indeed, two full weight bearing primary defects on the medial
femoral condyles were treated in this study with ChondroMimetic and demonstrated similarly high
degrees of total defect fill (mean: 95.85%) and high quality repair tissue with T2 relaxation times
comparable to native cartilage (means: 46.7 ms vs. 47.7 ms, respectively), in addition to satisfactory
clinical benefit.
A true study limitation was the lack of an active control group, such as microfracture, which
has been suggested by current regulatory guidance [38]. But use of an ipsilateral native cartilage
control ROI for quantitative structural outcomes provided an appropriate internal control for making
a determination of quality and durability of cartilage repair. Also, the small sample size of the
study could limit the interpretation of the results. However, the low variance in both clinical and
structural quantitative MRI outcomes nonetheless supports a consistency in repair that would likely be
maintained with a larger sample size. Long-term follow-up studies can also present challenges that
limit interpretation of study outcomes. For example, here, 14 procedures were conducted in the index
knee of 12 subjects over the 8-year follow-up period. However, it can be concluded that it is highly
unlikely that these procedures had any effect on the assessments conducted for this study. In 2 cases,
the procedures were not knee related (e.g., lung biopsy). The other 12 included: (1) hyaluronic acid
injections in 4 subjects performed at least 12 months prior to the extension study visit, and therefore
would be expected to have lost any therapeutic effect; (2) microfracture of new primary lesions in
3 subjects, although this would represent a worst case scenario since the procedure could worsen
the pain at the time of the extension study visit, or simply decrease the new pain associated with the
new lesion back to baseline levels; and (3) second-look arthroscopy in 5 subjects, conducted 1–2 years
post-operative by the investigator and unrelated to the study (e.g., to remove bone material from an
HTO; to remove malleolar screws from ankles).
The ChondroMimetic scaffold was designed to provide a cell-free cartilage repair alternative,
with biological components and architecture, conducive to the re-establishment of the subchondral
bone whilst supporting regeneration of articular cartilage. With time and experience, it has been
generally recognized that scaffolds are essential in supporting the processes of cartilage repair and
indeed, almost all current approaches have incorporated some type of scaffold. So-called “augmented
bone marrow stimulation” involves concurrent implantation of an exogenous scaffold (e.g., AMIC [12],
BST-CarGel [13], Biocartilage [39]), 3rd generation ACI techniques incorporate membranes to support
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cell delivery and residency (Hyalograft C [40], MACI [41]), and grafting techniques, by their nature,
involve implantation of natural osteochondral scaffolds [42]. The need to have cells, at all, is being
questioned when scaffolds alone, with their low cost and simplicity, bring equivalent results in a more
cost-effective manner [43].
5. Conclusions
Treatment of osteochondral defects in the knee with the ChondroMimetic scaffold was associated
with a consistently high degree of filling with a cartilage-like repair tissue over a long-term (7.9 year)
follow-up period, improved clinical scores, and noted lack of donor site morbidity, underscoring
potential benefits of a cell-free, single step scaffold from both a clinical and a health economic standpoint.
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ACI Autologous chondrocyte implantation
AMIC autologous matrix-induced chondrogenesis
CCI characterized chondrocyte implantation
FS SPGR fat-suppressed 3D spoiled gradient-echo
GAG glycosaminoglycan
kg kilogram




MRI Magnetic Resonance Imaging
PRP Platelet rich plasma
QoL Quality of life
ROI region-of-interest
T2 Transverse relaxation time
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